NexImmune, Inc. (NEXI) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Gaithersburg, MD, 美国. 现任CEO为 John Trainer.
NEXI 拥有 IPO日期为 2021-02-12, 6 名全职员工, 在 Other OTC, 市值为 $139.00.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
